Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020138371 - MODIFIED TCR AND PRODUCTION METHOD THEREFOR

Publication Number WO/2020/138371
Publication Date 02.07.2020
International Application No. PCT/JP2019/051311
International Filing Date 26.12.2019
IPC
A61P 37/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
C07K 14/725 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
C12N 5/074 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
074Adult stem cells
C12N 5/10 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/12 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
C12N 15/63 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
CPC
A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor;
10Cells modified by introduction of foreign genetic material
Applicants
  • キリンホールディングス株式会社 KIRIN HOLDINGS KABUSHIKI KAISHA [JP]/[JP]
  • 国立大学法人京都大学 KYOTO UNIVERSITY [JP]/[JP]
Inventors
  • 高柳 晋一郎 TAKAYANAGI Shinichiro
  • 長谷川 早紀 HASEGAWA Saki
  • 福本 健 FUKUMOTO Ken
  • 國里 篤志 KUNISATO Atsushi
  • 西川 慧 NISHIKAWA Satoshi
  • 金子 新 KANEKO Shin
Agents
  • 特許業務法人栄光特許事務所 Eikoh Patent Firm, P.C.
Priority Data
2018-24273326.12.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) MODIFIED TCR AND PRODUCTION METHOD THEREFOR
(FR) TCR MODIFIÉ ET SON PROCÉDÉ DE PRODUCTION
(JA) 改変TCR及びその製造方法
Abstract
(EN)
The purpose of the present invention is to provide a modified T-cell receptor (TCR) that allows a CD3 subunit to be held in a cell membrane and function without triggering responsiveness to an antigen. The present invention pertains to a modified TCR including a first polypeptide and a second polypeptide, wherein the first polypeptide includes a constant domain of human TCRα or a fragment of the constant domain, but does not include a variable domain of human TCRα, and the second polypeptide includes a constant domain of human TCRβ or a fragment of the constant domain, but does not include a variable domain of human TCRβ.
(FR)
La présente invention a pour objet de fournir un récepteur de cellule T (TCR) modifié qui permet à une sous-unité CD3 d'être maintenue dans une membrane cellulaire et de fonctionner sans déclencher de réaction à un antigène. La présente invention concerne un TCR modifié comprenant un premier polypeptide et un deuxième polypeptide, le premier polypeptide comprenant un domaine constant de TCRα humain ou un fragment du domaine constant, mais ne comprenant pas un domaine variable de TCRα humain, et le deuxième polypeptide comprenant un domaine constant de TCRβ humain ou un fragment du domaine constant, mais ne comprenant pas un domaine variable de TCRβ humain.
(JA)
本発明は、抗原応答性を惹起することなく、且つCD3サブユニットを細胞膜に保持させ、機能させることが出来る、改変T細胞受容体(TCR)を提供することを目的とする。本発明は、第1のポリペプチド及び第2のポリペプチドを含む改変TCRであって、第1のポリペプチドは、ヒトTCRαの定常領域又は該定常領域断片を含み、且つヒトTCRαの可変領域を含まないポリペプチドであり、第2のポリペプチドは、ヒトTCRβの定常領域又は該定常領域断片を含み、且つヒトTCRβの可変領域を含まないポリペプチドである、改変TCRに関する発明である。
Also published as
JP2020562463
Latest bibliographic data on file with the International Bureau